| Title |
|
Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role? |
|
|
| Publication Date |
|
| Author(s) |
|
| Type of document |
|
| DOI |
|
10.1111/j.1445-5994.2009.02143.x |
|
|
| Abstract |
|
Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs. |
|
|
| Link |
|
| Citation |
|
Internal Medicine Journal; 40(4): 300-3 |
|
|
| Jornal Title |
|
Internal Medicine Journal |
|
|
